Join

Compare · CHEK vs HOLX

CHEK vs HOLX

Side-by-side comparison of Check-Cap Ltd. (CHEK) and Hologic Inc. (HOLX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CHEK and HOLX operate in Medical Electronics (Health Care), so they compete in similar markets.
  • HOLX is the larger of the two at $17.60B, about 827.4x CHEK ($21.3M).
  • Over the past year, CHEK is up 100.6% and HOLX is up 17.8% - CHEK leads by 82.9 points.
  • HOLX has more recent analyst coverage (25 ratings vs 1 for CHEK).
PerformanceCHEK+100.62%HOLX+16.09%
2025-06-09+0.00%2025-11-26
MetricCHEKHOLX
Company
Check-Cap Ltd.
Hologic Inc.
Price
$1.61+0.63%
$76.02+0.49%
Market cap
$21.3M
$17.60B
1M return
+6.62%
+0.40%
1Y return
+100.62%
+17.77%
Industry
Medical Electronics
Medical Electronics
Exchange
NASDAQ
NASDAQ
IPO
2015
1990
News (4w)
0
0
Recent ratings
1
25
CHEK

Check-Cap Ltd.

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a disposable system attached to the patient's back via biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis and report generation. The company was founded in 2004 and is based in Isfiya, Israel.

HOLX

Hologic Inc.

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima quantitative viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. It has a collaboration with RadNet, Inc. to advance the use of artificial intelligence in breast health. Hologic, Inc. was founded in 1985 and is headquartered in Marlborough, Massachusetts.